Literature DB >> 15723574

Use of nifedipine in the treatment of hypertension.

Roberto Pontremoli1, Giovanna Leoncini, Angelica Parodi.   

Abstract

Hypertension is an important modifiable risk factor for cardiovascular disease; its prevention and treatment currently represent major health concerns around the world, especially in western countries. Effective, well-tolerated drugs such as dihydropyridine calcium channel blockers, to be used either alone or in combination treatments, play a key role in reducing cardiovascular morbidity and mortality. The extended-release formulation of nifedipine given once daily provides a relatively constant concentration profile and has proved to be effective in reducing blood pressure values. In the International Nifedipine gastrointestinal therapeutic system Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) study, it was demonstrated that nifedipine confers cardiovascular protection as effectively as diuretics in high-risk patients, with a smaller incidence of adverse metabolic consequences. Furthermore, two INSIGHT substudies demonstrated that nifedipine prevents the progression of carotid atherosclerosis and reduces the worsening of coronary calcifications, supporting the use of calcium channel blockers in hypertensive patients--especially those at high cardiovascular risk. This review discusses the existing clinical evidence supporting the use of nifedipine in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723574     DOI: 10.1586/14779072.3.1.43

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

1.  Efficient and green synthesis of novel hexahydro-5H-thiazolo[2',3':2,3]pyrimido[4,5-b]quinoline derivatives.

Authors:  Tooba Tabibi; Abbas Ali Esmaeili
Journal:  Mol Divers       Date:  2022-05-08       Impact factor: 2.943

2.  Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL).

Authors:  Rong Lv; Jianghua Chen; Huamin Wang; Jijun Wang; Hong Cheng; Rong Li; Wei Li; Tao Zhang; Lixin Wei; Qinkai Chen; Jian Huang; Feng Yu; Shizhong Shen; Henglan Wu; Cuihong Liu; Fuyuan Hong; Jie Liu; Xiaoru Zhang; Hua Xiao; Wenbin Song
Journal:  Adv Ther       Date:  2021-07-30       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.